First-line analysis of the effects of treatment on progression of structural changes in knee osteoarthritis over 24 months: data from the osteoarthritis initiative progression cohort
- PMID: 24336337
- DOI: 10.1136/annrheumdis-2013-203906
First-line analysis of the effects of treatment on progression of structural changes in knee osteoarthritis over 24 months: data from the osteoarthritis initiative progression cohort
Abstract
Objective: To determine, using data from participants enrolled in the progression cohort of the OAI, the effects of conventional osteoarthritis (OA) pharmacological treatment and those of the combination of glucosamine and chondroitin sulfate (Glu/CS) on knee structural changes.
Methods: Six hundred patients with knee OA were stratified based on whether or not they received for 24 consecutive months the OA conventional pharmacological treatment and/or Glu/CS. The main outcomes were knee structural changes, including the loss of joint space width (JSW) and of cartilage volume measured by quantitative MRI.
Results: Participants reported taking (+) (n=300) or not taking (-) (n=300) OA treatment (analgesic/NSAIDs). The +analgesic/NSAIDs participants had higher Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores (p<0.001) and smaller JSW (p=0.01), reflecting more severe disease at baseline. In the -analgesic/NSAIDs group, participants taking Glu/CS had significantly reduced loss of cartilage volume at 24 months in the medial central plateau (p=0.007). Further subdivision revealed that this effect of Glu/CS occurred in participants with a higher severity of the disease (JSW≤median). In the +analgesic/NSAIDs group, those taking Glu/CS had significantly reduced loss of cartilage volume in the global plateau at 12 months (p=0.05), and in the central plateau at 24 months (p=0.05). These effects occurred in participants with less disease severity (JSW>median). By contrast, no significant reduction in JSW was found between all groups.
Conclusions: In +analgesic/NSAIDs groups and -analgesic/NSAIDs groups, participants who took Glu/CS had reduced loss of cartilage volume over 24 months in subregions when assessed with qMRI, arguing for a disease-modifying effect of Glu/CS which could not be identified by X-rays.
Keywords: Knee Osteoarthritis; Magnetic Resonance Imaging; Treatment.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Comment in
-
Concerns about report suggesting glucosamine and chondroitin protect against cartilage loss.Ann Rheum Dis. 2015 Aug;74(8):e38. doi: 10.1136/annrheumdis-2015-207479. Epub 2015 Mar 10. Ann Rheum Dis. 2015. PMID: 25757868 No abstract available.
-
Response to: 'Concerns about report suggesting glucosamine and chondroitin protect against cartilage loss' by Felson.Ann Rheum Dis. 2015 Aug;74(8):e39. doi: 10.1136/annrheumdis-2015-207491. Epub 2015 Apr 1. Ann Rheum Dis. 2015. PMID: 25834141 No abstract available.
Similar articles
-
Impact of disease treatments on the progression of knee osteoarthritis structural changes related to meniscal extrusion: Data from the OAI progression cohort.Semin Arthritis Rheum. 2015 Dec;45(3):257-67. doi: 10.1016/j.semarthrit.2015.05.001. Epub 2015 May 15. Semin Arthritis Rheum. 2015. PMID: 26094904
-
Risk factors associated with the loss of cartilage volume on weight-bearing areas in knee osteoarthritis patients assessed by quantitative magnetic resonance imaging: a longitudinal study.Arthritis Res Ther. 2007;9(4):R74. doi: 10.1186/ar2272. Arthritis Res Ther. 2007. PMID: 17672891 Free PMC article.
-
Long-Term Effects of Glucosamine and Chondroitin Sulfate on the Progression of Structural Changes in Knee Osteoarthritis: Six-Year Followup Data From the Osteoarthritis Initiative.Arthritis Care Res (Hoboken). 2016 Oct;68(10):1560-6. doi: 10.1002/acr.22866. Epub 2016 Sep 16. Arthritis Care Res (Hoboken). 2016. PMID: 26881338
-
Chondroprotection and the prevention of osteoarthritis progression of the knee: a systematic review of treatment agents.Am J Sports Med. 2015 Mar;43(3):734-44. doi: 10.1177/0363546514533777. Epub 2014 May 27. Am J Sports Med. 2015. PMID: 24866892 Review.
-
Clinical review of chondroitin sulfate in osteoarthritis.Osteoarthritis Cartilage. 2008;16 Suppl 3:S19-21. doi: 10.1016/j.joca.2008.06.006. Epub 2008 Jul 31. Osteoarthritis Cartilage. 2008. PMID: 18674931 Review.
Cited by
-
Profiling Bioactive Components of Natural Eggshell Membrane (NEM) for Cartilage Protection and Its Protective Effect on Oxidative Stress in Human Chondrocytes.Int J Mol Sci. 2024 Oct 21;25(20):11304. doi: 10.3390/ijms252011304. Int J Mol Sci. 2024. PMID: 39457086 Free PMC article.
-
Evaluation of the Cartinorm Use in the Therapy of Patients with Knee Osteoarthritis.Mater Sociomed. 2024;36(1):54-58. doi: 10.5455/msm.2024.36.54-58. Mater Sociomed. 2024. PMID: 38590589 Free PMC article.
-
A Machine Learning Model to Predict Knee Osteoarthritis Cartilage Volume Changes over Time Using Baseline Bone Curvature.Biomedicines. 2022 May 26;10(6):1247. doi: 10.3390/biomedicines10061247. Biomedicines. 2022. PMID: 35740270 Free PMC article.
-
Non-Surgical Treatment of Knee Osteoarthritis: Multidisciplinary Italian Consensus on Best Practice.Ther Clin Risk Manag. 2021 May 28;17:507-530. doi: 10.2147/TCRM.S288196. eCollection 2021. Ther Clin Risk Manag. 2021. PMID: 34093017 Free PMC article.
-
Clinical risk factors associated with radiographic osteoarthritis progression among people with knee pain: a longitudinal study.Arthritis Res Ther. 2021 Jun 4;23(1):160. doi: 10.1186/s13075-021-02540-9. Arthritis Res Ther. 2021. PMID: 34088340 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources